2024 Event Guide
*data provided by Beacon
Topics Discussed by These Companies
Clinical updates on; DeltEx DRI Auto, DeltEx Allo, DeltEx nsCAR-T INB-300 & iPSC Derived Gamma-Delta T Cells
Clinical design case study on best practice when designing and running a CAR-T clinical trial in autoimmune and oncology indications
Clinical findings on Vd2 and Vd1 gamma delta T cells that evaluate the efficacy, safety and benefits of gamma delta cell therapies in treating AcutAML
Novel preclinical dual CAR architecture targeting and engineering to establish an allogeneic dual targeting CAR that will consist of CSPG4 and CD70
Reviewing the development of their off-the-shelf lead product and setting up current UK based clinical trials
Introduction to the Immunocore ImmTAX discovery platform and the first approved gamma delta TCR bi-specific therapeutic